$2.370
+0.020 (+0.85%)At close
LNAI News
LNAI Events
Lunai Bioworks and BrainStorm Announce Strategic Collaboration
Lunai Bioworks' (LNAI) wholly owned subsidiary BioSymetrics and BrainStorm (BCLI) announced a strategic collaboration and Letter of Intent to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the LouLou Foundation. The collaboration combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm Therapeutics' proprietary human-derived organoid systems to create an integrated translational engine for neurology drug discovery. The companies intend to generate high-confidence therapeutic programs designed for pharmaceutical partnering, licensing, and downstream development. Initial efforts will focus on rare genetic epilepsies and neurodegenerative diseases, including Parkinson's disease. As part of the collaboration, the companies are integrating BrainStorm's Parkinson's disease midbrain organoid foundation model with BioSymetrics' proprietary analysis of the Parkinson's Progression Markers Initiative dataset, to identify progression-associated biomarkers and high-confidence therapeutically actionable targets. The program is intended to support precision medicine strategies and accelerate the development of differentiated CNS therapeutics.
Lunai Bioworks Signs LOI with Geneial for Strategic Collaboration
Lunai Bioworks and Geneial, a precision medicine data infrastructure and patient engagement company, announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent, or LOI, with Geneial to pursue a strategic collaboration in rare neurological disorders. The collaboration is designed to support rare disease research and advocacy groups in converting fragmented, patient-generated data into actionable drug development programs, including the creation and activation of trial-ready patient cohorts that can support pharmaceutical partnerships. Under the proposed collaboration, BioSymetrics and Geneial plan to: integrate and standardize patient-led rare disease datasets; identify defined patient subgroups for clinical development; generate actionable insights to support therapeutic programs; enable the activation of trial-ready cohorts for pharma and biotech engagement. The companies expect to pursue commercial partnerships enabled by these efforts. The initial focus will include select rare neurodevelopmental disorders, with the goal of building scalable programs that can expand over time. The LOI is non-binding.
Lunai Bioworks Executes $20M Acquisition of BBB Technology
Lunai Bioworks has executed a binding $20M strategic transaction to acquire blood-brain barrier, or BBB, delivery technology and central nervous system, or CNS, Alzheimer's drug assets from the Clemann Group, SAS or its assignee. The transaction is structured as Series B Convertible Preferred at a fixed conversion price of $1.50 per share, subject to a 19.9% beneficial ownership limitation. The transaction aims to strengthen Lunai's CNS Alzheimer's pipeline by pairing biological target identification with a proven delivery method and expand the company's ability to develop next-generation treatments across a broad range of CNS disorders where traditional drugs struggle to penetrate the brain effectively, offering the potential for improved safety and efficacy.
Lunai Bioworks Forms National Consortium to Accelerate Chemical Countermeasure Development
Lunai Bioworks announced the formation of a national consortium designed to accelerate the discovery and development of chemical countermeasures for emerging battlefield and terrorism threats. The Pathfinder Consortium, a national academic-industry alliance designed to consolidate historically siloed U.S. chemical warfare preparedness resources into a unified, execution-ready infrastructure capable of accelerating medical countermeasure development to approximately three years. Unlike traditional pharmaceutical development cycles, chemical countermeasures can follow accelerated regulatory pathways. The Pathfinder model is structured to: Demonstrate efficacy in yeast and cell-based systems Validate therapeutic effects in FDA-recognized zebrafish models Complete two confirmatory animal studies Conduct a 50-person Phase I safety study The full process can be completed in approximately 36 months. In many cases, existing FDA-approved drugs may be repurposed, potentially reducing timelines even further. Pathfinder includes collaboration with nationally recognized experts, including: Dr. Calum MacRae, Brigham and Women's Hospital and Harvard Medical School; Dr. Vik Bebarta, Colonel, U.S. Air Force Reserve; University of Colorado; Dr. Randall Peterson, University of Utah; Dr. Vincent Jo Davidson, Purdue University.
Lunai Bioworks Secures U.S. Patent for Debiasing Drug Discovery Data
Lunai Bioworks announced the issuance of a U.S. patent titled "Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions." The newly issued patent protects the foundational first step of Lunai's proprietary closed-loop disease reverse engineering platform, multimodal data standardization and structural bias removal prior to predictive modeling. Lunai's patented architecture systematically detects, standardizes, and removes structural bias across multimodal inputs before downstream artificial intelligence modeling begins. By protecting this core data layer, Lunai aims to strengthen its ability to accurately identify biologically coherent patient subtypes and trace those subtypes to the gene networks most strongly associated with each disease type.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.